Clinical Trials Browser

Neoplasms, Thyroid Diseases

NCT03899155 2026-04-01

Pan Tumor Rollover Study

Phase 2 Recruiting

1,500 enrolled

Tumor-Agnostic

Neoplasms

NCT00940225 2024-04-25

Study of Cabozantinib (XL184) in Adults With Advanced Malignancies

Phase 2 Completed

730 enrolled 25 charts

BreastDermatologicGastrointestinalGenitourinaryGynecologicThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Hepatocellular, Melanoma, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Small Cell Lung Carcinoma

NCT05289856 2024-03-07

Cabozantinib in Combination With Avelumab in Patients Refractory to Standard Chemotherapy With Advanced Neuroendocrine Neoplasias G3 (NEN G3)

Phase 2 Unknown

30 enrolled

Tumor-Agnostic

Neoplasms

NCT02925234 2024-01-24

DRUP

Phase 2 Recruiting

1,550 enrolled

Tumor-Agnostic

Neoplasms

NCT03542877 2022-07-15

Investigating Cabozantinib in Patients With Refractory Metastatic Colorectal Cancer

Phase 2 Completed

44 enrolled 19 charts

Gastrointestinal

Neoplasms, Colorectal Neoplasms

NCT03239015 2022-03-04

Efficacy and Safety of Precision Therapy in Refractory Tumor

Phase 2 Unknown

300 enrolled

Tumor-Agnostic

Neoplasms

NCT01428219 2017-12-12

Trial of Cabozantinib (XL184) in Castrate-Resistant Prostate Cancer Metastatic to Bone

Phase 2 Terminated

25 enrolled 12 charts

Tumor-Agnostic

Neoplasm Metastasis, Neoplasms

Clinical Trials

CABOTHYROID

Pan Tumor Rollover Study

Study of Cabozantinib (XL184) in Adults With Advanced Malignancies

Cabozantinib in Combination With Avelumab in Patients Refractory to Standard Chemotherapy With Advanced Neuroendocrine Neoplasias G3 (NEN G3)

DRUP

Investigating Cabozantinib in Patients With Refractory Metastatic Colorectal Cancer

Efficacy and Safety of Precision Therapy in Refractory Tumor

Trial of Cabozantinib (XL184) in Castrate-Resistant Prostate Cancer Metastatic to Bone